Efficiency of Quercetin and Trimetasidine in Patients With Covid-19 and Concomitant Chronic Coronary Syndrome: Effect on Systemic Inflammation

Patients with cardiovascular disease suffer a more severe course of COVID-19, requiring enhanced oxygen therapy, including invasive methods, and higher mortality.At the same time, SARS-CoV2 can directly or indirectly adversely affect the course of chronic coronary syndromes, independent of the use of optimal treatment.The use of quercetin in combination with trimetazidine promises new opportunities for the treatment of patients with COVID-19 with concomitant cardiovascular disease, offering an integrated approach to reduce inflammation, oxidative stress, and improve heart muscle function.Quercetin can help reduce symptoms, shorten the duration of the disease and prevent the development of complications, especially in patients with CVD.Trimetazidine, on the other hand, acts as a metabolic modulator of the heart muscle, optimizing oxygen consumption and improving the energy metabolism of cardiomyocytes.In the context of COVID-19, this may help maintain cardiac function in patients with concomitant CVD, reducing the risk of developing heart failure and other complications.The aim of the study was to evaluate the efficacy of quercetin and its combination with trimetazidine compared to standard therapy for the treatment of pneumonia associated with COVID-19 and concomitant chronic coronary syndromes.For the study, 92 patients with COVID-19 and concomitant chronic coronary syndromes were selected and divided into three groups: the first group received only standard treatment (n=31), the second group received additional quercetin intravenously for 7 days (n=29), and the third group received quercetin in combination with trimetazidine for 7 days (n=32).The study of inflammatory markers revealed that the combination of quercetin with trimetazidine reduces inflammatory activity, which is reflected in a decrease in the SIRI and AISI inflammation indices (p<0.001).There was also a decrease in transaminase activity and an improvement in the level of GFR.